{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T04:06:41Z","timestamp":1777090001283,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["204419"],"award-info":[{"award-number":["204419"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Human cytomegalovirus (CMV) is a common herpesvirus which is estimated to infect 83% of the global population. Whilst many infections are asymptomatic, it is an important cause of morbidity and mortality, particularly for immunocompromised people and for infants who are congenitally infected. A vaccine against CMV has been stated as a public health priority, but there are gaps in our understanding of CMV epidemiology. To guide potential future vaccination strategies, our aim was to examine risk factors for CMV seropositivity in young people in England.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Health Survey for England (HSE) is an annual, cross-sectional representative survey of households in England during which data are collected through questionnaires, and blood samples are taken. We randomly selected individuals who participated in the HSE 2002, aiming for 25 participants of each sex in each single year age group from 11 to 24\u2009years. Stored samples were tested for CMV antibodies. We undertook descriptive and regression analyses of CMV seroprevalence and risk factors for infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Demographic data and serostatus were available for 732 individuals, of whom 175 (23.7%) were CMV-seropositive. CMV seroprevalence was associated with age, with 18.3% seropositive at 11\u201314\u2009years compared to 28.3% at 22\u201324\u2009years. CMV serostatus was also higher in people of non-white ethnicity (adjusted odds ratio [aOR] 6.22, 95% confidence interval [CI] 3.47\u201311.14), and in adults who were seropositive for EBV (aOR 2.08 [1.06\u20134.09]). There was no evidence that smoking status, occupation, body mass index and region of England were associated with CMV serostatus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CMV seroprevalence is strongly associated with ethnicity, and modestly increases with age in 11\u201324-year-olds. A greater understanding of the transmission dynamics of CMV, and the impact of this on CMV-associated morbidity and mortality, is necessary to inform effective vaccination strategies when a vaccine for CMV becomes available.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-020-05572-9","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T13:03:39Z","timestamp":1606136619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Factors associated with cytomegalovirus serostatus in young people in England: a cross-sectional study"],"prefix":"10.1186","volume":"20","author":[{"given":"Joanne R.","family":"Winter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham S.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia G.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna E. A.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4022-3447","authenticated-orcid":false,"given":"Helen R.","family":"Stagg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"5572_CR1","doi-asserted-by":"publisher","first-page":"e2034","DOI":"10.1002\/rmv.2034","volume":"29","author":"M Zuhair","year":"2019","unstructured":"Zuhair M, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019;29:e2034.","journal-title":"Rev Med Virol"},{"key":"5572_CR2","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/eji.201570044","volume":"45","author":"R Arens","year":"2015","unstructured":"Arens R, Remmerswaal EBM, Bosch JA, van Lier RAW. 5th international workshop on CMV and Immunosenescence - a shadow of cytomegalovirus infection on immunological memory. Eur J Immunol. 2015;45:954\u20137.","journal-title":"Eur J Immunol"},{"key":"5572_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/jmv.24450","volume":"88","author":"D Navarro","year":"2016","unstructured":"Navarro D. Expanding role of cytomegalovirus as a human pathogen: Cytomegalovirus and human disease. J Med Virol. 2016;88:1103\u201312.","journal-title":"J Med Virol"},{"key":"5572_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/00000441-197811000-00010","volume":"276","author":"A Evans","year":"1978","unstructured":"Evans A. Infectious mononucleosis and related syndromes. Am J Med Sci. 1978;276:325\u201340.","journal-title":"Am J Med Sci"},{"key":"5572_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0163-7258(03)00034-2","volume":"98","author":"S Landolfo","year":"2003","unstructured":"Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol Ther. 2003;98:269\u201397.","journal-title":"Pharmacol Ther"},{"key":"5572_CR6","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/cid\/cit083","volume":"56","author":"E Gkrania-Klotsas","year":"2013","unstructured":"Gkrania-Klotsas E, et al. Seropositivity and higher immunoglobulin G antibody levels against Cytomegalovirus are associated with mortality in the population-based European prospective investigation of Cancer\u2013Norfolk cohort. Clin Infect Dis. 2013;56:1421\u20137.","journal-title":"Clin Infect Dis"},{"key":"5572_CR7","doi-asserted-by":"publisher","first-page":"e16103","DOI":"10.1371\/journal.pone.0016103","volume":"6","author":"AM Simanek","year":"2011","unstructured":"Simanek AM, et al. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. Plos One. 2011;6:e16103.","journal-title":"Plos One"},{"key":"5572_CR8","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/aje\/kwq062","volume":"171","author":"GC Wang","year":"2010","unstructured":"Wang GC, et al. Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am J Epidemiol. 2010;171:1144\u201352.","journal-title":"Am J Epidemiol"},{"key":"5572_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jama.2009.4","volume":"301","author":"TE Strandberg","year":"2009","unstructured":"Strandberg TE, Pitkala KH, Tilvis RS. Cytomegalovirus antibody level and mortality among community-dwelling older adults with stable cardiovascular disease. JAMA. 2009;301:380\u20132.","journal-title":"JAMA"},{"key":"5572_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/1743-422X-8-485","volume":"8","author":"Q Lepiller","year":"2011","unstructured":"Lepiller Q, Tripathy MK, Di Martino V, Kantelip B, Herbein G. Increased HCMV seroprevalence in patients with hepatocellular carcinoma. Virol J. 2011;8:485.","journal-title":"Virol J"},{"key":"5572_CR11","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/infdis\/jis620","volume":"206","author":"E Gkrania-Klotsas","year":"2012","unstructured":"Gkrania-Klotsas E, et al. Higher immunoglobulin G antibody levels against Cytomegalovirus are associated with incident ischemic heart disease in the population-based EPIC-Norfolk cohort. J Infect Dis. 2012;206:1897\u2013903.","journal-title":"J Infect Dis"},{"key":"5572_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1352458513494489","volume":"20","author":"E Sundqvist","year":"2014","unstructured":"Sundqvist E, et al. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. 2014;20:165\u201373.","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"184","key":"5572_CR13","first-page":"3417","volume":"1950","author":"PJEJ van de Berg","year":"2010","unstructured":"van de Berg PJEJ, et al. Cytomegalovirus infection reduces telomere length of the circulating T cell pool. J Immunol Baltim Md. 2010;1950(184):3417\u201323.","journal-title":"J Immunol Baltim Md"},{"key":"5572_CR14","doi-asserted-by":"crossref","unstructured":"Hosie L, et al. Cytomegalovirus-specific T cells restricted by HLA-Cw*0702 increase markedly with age and dominate the CD8+ T-cell repertoire in older people. Front Immunol. 2017;8:1776.","DOI":"10.3389\/fimmu.2017.01776"},{"key":"5572_CR15","doi-asserted-by":"publisher","first-page":"e1005832","DOI":"10.1371\/journal.ppat.1005832","volume":"12","author":"A Pachnio","year":"2016","unstructured":"Pachnio A, et al. Cytomegalovirus infection leads to development of high frequencies of cytotoxic virus-specific CD4+ T cells targeted to vascular endothelium. PLoS Pathog. 2016;12:e1005832.","journal-title":"PLoS Pathog"},{"key":"5572_CR16","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1586\/erv.10.125","volume":"9","author":"H Sung","year":"2010","unstructured":"Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines. 2010;9:1303\u201314.","journal-title":"Expert Rev Vaccines"},{"key":"5572_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1086\/421999","volume":"39","author":"JF Modlin","year":"2004","unstructured":"Modlin JF, et al. Vaccine development to prevent Cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis. 2004;39:233\u20139.","journal-title":"Clin Infect Dis"},{"key":"5572_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1017\/S0950268808000551","volume":"137","author":"JB Dowd","year":"2009","unstructured":"Dowd JB, Aiello AE, Alley DE. Socioeconomic Disparities in the Seroprevalence of Cytomegalovirus Infection in the U.S. Population: NHANES III. Epidemiol Infect. 2009;137:58\u201365.","journal-title":"Epidemiol Infect"},{"key":"5572_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.annepidem.2012.06.099","volume":"22","author":"H Levine","year":"2012","unstructured":"Levine H, et al. Seroepidemiology of Epstein-Barr virus and cytomegalovirus among Israeli male young adults. Ann Epidemiol. 2012;22:783\u20138.","journal-title":"Ann Epidemiol"},{"key":"5572_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1186\/s12879-019-4578-y","volume":"19","author":"JR Winter","year":"2019","unstructured":"Winter JR, et al. Predictors of Epstein-Barr virus serostatus in young people in England. BMC Infect Dis. 2019;19:1007.","journal-title":"BMC Infect Dis"},{"key":"5572_CR21","doi-asserted-by":"crossref","unstructured":"Lachmann R, et al. Cytomegalovirus (CMV) seroprevalence in the adult population of Germany. Plos One. 2018;13:e0200267.","DOI":"10.1371\/journal.pone.0200267"},{"key":"5572_CR22","doi-asserted-by":"crossref","unstructured":"Pembrey L, et al. Seroprevalence of Cytomegalovirus, Epstein Barr Virus and Varicella Zoster Virus among Pregnant Women in Bradford: A Cohort Study. Plos One. 2013;8:e81881.","DOI":"10.1371\/journal.pone.0081881"},{"key":"5572_CR23","doi-asserted-by":"crossref","unstructured":"Pembrey L, et al. Cytomegalovirus, Epstein-Barr virus and varicella zoster virus infection in the first two years of life: a cohort study in Bradford, UK. BMC Infect Dis. 2017;17(220):1-18.","DOI":"10.1186\/s12879-017-2319-7"},{"key":"5572_CR24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/pai.13093","volume":"30","author":"L Pembrey","year":"2019","unstructured":"Pembrey L, Waiblinger D, Griffiths P, Wright J. Age at cytomegalovirus, Epstein Barr virus and varicella zoster virus infection and risk of atopy: the born in Bradford cohort, UK. Pediatr Allergy Immunol. 2019;30:604\u201313.","journal-title":"Pediatr Allergy Immunol"},{"key":"5572_CR25","unstructured":"Deverill, C. et al. Health Survey for England 2002: The Health of Children and Young People. Methodology & Documentation. (The Stationary Office, 2002)."},{"key":"5572_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-45381-y","volume":"9","author":"L Gosc\u00e9","year":"2019","unstructured":"Gosc\u00e9 L, Winter JR, Taylor GS, Lewis JEA, Stagg HR. Modelling the dynamics of EBV transmission to inform a vaccine target product profile and future vaccination strategy. Sci Rep. 2019;9:1\u20139.","journal-title":"Sci Rep"},{"key":"5572_CR27","volume-title":"Estimates of the population for the UK, England and Wales, Scotland and Northern Ireland","author":"Office for National Statistics","year":"2018","unstructured":"Office for National Statistics. Estimates of the population for the UK, England and Wales, Scotland and Northern Ireland. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesforukenglandandwalesscotlandandnorthernireland (2018)."},{"key":"5572_CR28","unstructured":"Office for National Statistics. Census boundary data [United Kingdom]. https:\/\/census.ukdataservice.ac.uk\/get-data\/boundary-data.aspx (2011). Accessed 16 Jan 2018."},{"key":"5572_CR29","volume-title":"Census aggregate data","author":"UK Data Service","year":"2001","unstructured":"UK Data Service. Census aggregate data. https:\/\/census.ukdataservice.ac.uk\/get-data\/aggregate-data.aspx (2001)."},{"key":"5572_CR30","unstructured":"UKB : Data-Field 23054. https:\/\/biobank.ndph.ox.ac.uk\/showcase\/field.cgi?id=23054. Accessed 11 Oct 2020."},{"key":"5572_CR31","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1017\/S0950268808001258","volume":"137","author":"AJ Vyse","year":"2009","unstructured":"Vyse AJ, Hesketh LM, Pebody RG. The burden of infection with cytomegalovirus in England and Wales: how many women are infected in pregnancy? Epidemiol Infect. 2009;137:526\u201333.","journal-title":"Epidemiol Infect"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05572-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-05572-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05572-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T09:15:23Z","timestamp":1669713323000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05572-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5572"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05572-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"20 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the University College London Research Ethics Committee (5683\/002). The HSE obtained informed written consent for blood samples to be collected and stored for future analyses.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GT reports personal fees from Genocea Biosciences, outside the submitted work. CJ is an Associate Editor at BMC Public Health. All other authors have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"875"}}